ImmunoReagents and Funakoshi will work closely together to bring top quality antibodies to the Japanese biotech, life science, and medical community. Japan is quickly becoming one of the world’s most prominent biotech regions. Japan also hosts some of the finest public research institutions, and universities. According to a study by the Japan Bio Industry Association (JBA: 2008), there were 714 biotechnology companies in Japan in 2007, and over 1000 pharmaceutical companies.
"This is a great opportunity for our company." said Ann Black, President and CEO of ImmunoReagents. "Funakoshi is a trusted, well established company that will allow us to launch our products into a rich biotech region quickly. We look forward to building a lasting business relationship.”
ImmunoReagents is a leading global manufacturer of quality polyclonal antibodies used in research and in vitro diagnostics. They offer a wide range of secondary antibodies covering a broad spectrum of immunoglobulins from various species. Antibodies include various levels of cross species absorptions to provide high specificity. The Company also manufactures primary polyclonal antibodies to hormones, cancer markers, cardiac markers and serum proteins. In addition to its vast product lines, ImmunoReagents also provides custom manufacturing to meet specific customer requirements while adhering to cGMP guidelines and ISO quality systems requirements. The Company is located on NCSU’s Centennial Campus, the University-owned and operated research park and technology campus.
More information about ImmunoReagents:
About Funakoshi Co. Ltd.
Funakoshi Co., Ltd. is a leading distributor of research reagents and instruments for researchers in the life science field. Their corporate mission is to provide products to a broad range of customers throughout their worldwide network.
More information about Funakoshi: http://www.funakoshi.co.jp